The latest price target for ADC Therapeutics (NYSE:ADCT) was reported by Guggenheim on March 31, 2025. The analyst firm set a price target for $7.00 expecting ADCT to rise to within 12 months (a possible 503.45% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE:ADCT) was provided by Guggenheim, and ADC Therapeutics maintained their buy rating.

The last upgrade for ADC Therapeutics SA happened on August 10, 2023 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for ADC Therapeutics SA.

The last downgrade for ADC Therapeutics SA happened on November 9, 2023 when TD Cowen changed their price target from N/A to N/A for ADC Therapeutics SA.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on March 31, 2025 so you should expect the next rating to be made available sometime around March 31, 2026.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a maintained with a price target of $10.00 to $7.00. The current price ADC Therapeutics (ADCT) is trading at is $1.16, which is out of the analyst’s predicted range.